CN109349618A - Constipation tailored version clinical nutrition formula and preparation method thereof - Google Patents
Constipation tailored version clinical nutrition formula and preparation method thereof Download PDFInfo
- Publication number
- CN109349618A CN109349618A CN201811237151.3A CN201811237151A CN109349618A CN 109349618 A CN109349618 A CN 109349618A CN 201811237151 A CN201811237151 A CN 201811237151A CN 109349618 A CN109349618 A CN 109349618A
- Authority
- CN
- China
- Prior art keywords
- parts
- constipation
- powder
- clinical nutrition
- tailored version
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010010774 Constipation Diseases 0.000 title claims abstract description 106
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 53
- 230000035764 nutrition Effects 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 238000009472 formulation Methods 0.000 title description 10
- 229940088594 vitamin Drugs 0.000 claims abstract description 31
- 229930003231 vitamin Natural products 0.000 claims abstract description 31
- 235000013343 vitamin Nutrition 0.000 claims abstract description 31
- 239000011782 vitamin Substances 0.000 claims abstract description 31
- 235000013305 food Nutrition 0.000 claims abstract description 29
- 230000035622 drinking Effects 0.000 claims abstract description 25
- 235000008216 herbs Nutrition 0.000 claims abstract description 25
- 230000010354 integration Effects 0.000 claims abstract description 25
- 239000004615 ingredient Substances 0.000 claims abstract description 19
- 235000005911 diet Nutrition 0.000 claims abstract description 17
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 17
- 230000037213 diet Effects 0.000 claims abstract description 15
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 74
- 235000013350 formula milk Nutrition 0.000 claims description 39
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 25
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 25
- 235000015097 nutrients Nutrition 0.000 claims description 20
- 235000016641 Syzygium paniculatum Nutrition 0.000 claims description 18
- 244000223082 Syzygium paniculatum Species 0.000 claims description 18
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 18
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 17
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 17
- 244000131360 Morinda citrifolia Species 0.000 claims description 17
- 241000245665 Taraxacum Species 0.000 claims description 17
- 235000017524 noni Nutrition 0.000 claims description 17
- 241000196324 Embryophyta Species 0.000 claims description 16
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 16
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 16
- 244000144730 Amygdalus persica Species 0.000 claims description 15
- 210000003038 endothelium Anatomy 0.000 claims description 15
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 15
- 229920001503 Glucan Polymers 0.000 claims description 14
- 241000219784 Sophora Species 0.000 claims description 14
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 14
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 13
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 13
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 13
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 13
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 12
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 12
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 12
- 239000000839 emulsion Substances 0.000 claims description 11
- 239000010903 husk Substances 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- 244000061520 Angelica archangelica Species 0.000 claims description 10
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 10
- 241000234435 Lilium Species 0.000 claims description 10
- 244000246386 Mentha pulegium Species 0.000 claims description 10
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 10
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 10
- 235000001050 hortel pimenta Nutrition 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 235000014633 carbohydrates Nutrition 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 4
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 4
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 4
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 4
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 4
- 244000197580 Poria cocos Species 0.000 claims description 4
- 235000008599 Poria cocos Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 4
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 241000208688 Eucommia Species 0.000 claims description 3
- 241000237502 Ostreidae Species 0.000 claims description 3
- 235000008184 Piper nigrum Nutrition 0.000 claims description 3
- 244000203593 Piper nigrum Species 0.000 claims description 3
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 3
- 241000219780 Pueraria Species 0.000 claims description 3
- 240000002547 Rosa roxburghii Species 0.000 claims description 3
- 235000000640 Rosa roxburghii Nutrition 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 235000013614 black pepper Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- 235000020243 first infant milk formula Nutrition 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002213 flavones Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940100688 oral solution Drugs 0.000 claims description 3
- 235000020636 oyster Nutrition 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 108010001441 Phosphopeptides Proteins 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 244000088415 Raphanus sativus Species 0.000 claims 4
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 244000170916 Paeonia officinalis Species 0.000 claims 1
- 235000006484 Paeonia officinalis Nutrition 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 230000008859 change Effects 0.000 abstract description 13
- 230000000638 stimulation Effects 0.000 abstract description 8
- 208000002720 Malnutrition Diseases 0.000 abstract description 4
- 230000007812 deficiency Effects 0.000 abstract description 4
- 208000015706 neuroendocrine disease Diseases 0.000 abstract description 3
- 235000018343 nutrient deficiency Nutrition 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 35
- 210000001035 gastrointestinal tract Anatomy 0.000 description 23
- 210000000936 intestine Anatomy 0.000 description 23
- 230000006870 function Effects 0.000 description 22
- 241000220259 Raphanus Species 0.000 description 21
- 230000013872 defecation Effects 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 230000000968 intestinal effect Effects 0.000 description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 229920001202 Inulin Polymers 0.000 description 14
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 14
- 229940029339 inulin Drugs 0.000 description 14
- 210000005036 nerve Anatomy 0.000 description 14
- 230000002496 gastric effect Effects 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 229920002774 Maltodextrin Polymers 0.000 description 12
- 239000005913 Maltodextrin Substances 0.000 description 12
- 229940035034 maltodextrin Drugs 0.000 description 12
- 201000010099 disease Diseases 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 210000000952 spleen Anatomy 0.000 description 10
- 229920001353 Dextrin Polymers 0.000 description 9
- 239000004375 Dextrin Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 235000019425 dextrin Nutrition 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 239000004006 olive oil Substances 0.000 description 9
- 235000008390 olive oil Nutrition 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 235000013399 edible fruits Nutrition 0.000 description 8
- 208000002551 irritable bowel syndrome Diseases 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000011691 vitamin B1 Substances 0.000 description 8
- 239000011715 vitamin B12 Substances 0.000 description 8
- 239000011716 vitamin B2 Substances 0.000 description 8
- 239000011726 vitamin B6 Substances 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 229930003427 Vitamin E Natural products 0.000 description 7
- 235000010489 acacia gum Nutrition 0.000 description 7
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000835 fiber Substances 0.000 description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 210000002429 large intestine Anatomy 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000008855 peristalsis Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- 235000019165 vitamin E Nutrition 0.000 description 7
- 239000011709 vitamin E Substances 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- 241000206575 Chondrus crispus Species 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 210000002460 smooth muscle Anatomy 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001147 anti-toxic effect Effects 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 235000013312 flour Nutrition 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 235000003132 food thickener Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 239000000932 sedative agent Substances 0.000 description 5
- 230000001624 sedative effect Effects 0.000 description 5
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 239000011162 core material Substances 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000004519 grease Substances 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 229920002752 Konjac Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000007413 intestinal health Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008141 laxative Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000000955 neuroendocrine Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000143060 Americamysis bahia Species 0.000 description 2
- 244000247812 Amorphophallus rivieri Species 0.000 description 2
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 101800001982 Cholecystokinin Proteins 0.000 description 2
- 102100025841 Cholecystokinin Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002581 Glucomannan Polymers 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 102000002020 Protease-activated receptors Human genes 0.000 description 2
- 108050009310 Protease-activated receptors Proteins 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000002255 anal canal Anatomy 0.000 description 2
- 230000000049 anti-anxiety effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940107137 cholecystokinin Drugs 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 210000002592 gangliocyte Anatomy 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940046240 glucomannan Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000007149 gut brain axis pathway Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000000252 konjac Substances 0.000 description 2
- 235000010485 konjac Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000001809 melena Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960004085 mosapride Drugs 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- -1 oligofructose Chemical compound 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000001072 progestational effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001543 purgative effect Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- HUJXHFRXWWGYQH-UHFFFAOYSA-O sinapine Chemical compound COC1=CC(\C=C\C(=O)OCC[N+](C)(C)C)=CC(OC)=C1O HUJXHFRXWWGYQH-UHFFFAOYSA-O 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108091005482 5-HT4 receptors Proteins 0.000 description 1
- IPQVTOJGNYVQEO-UHFFFAOYSA-N 9-[2-carboxy-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracen-9-yl]-4-hydroxy-10-oxo-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9h-anthracene-2-carboxylic acid Chemical class OC1C(O)C(O)C(CO)OC1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1C2C1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(OC3C(C(O)C(O)C(CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241000271309 Aquilaria crassna Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 102000005702 Calcium-Activated Potassium Channels Human genes 0.000 description 1
- 108010045489 Calcium-Activated Potassium Channels Proteins 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 235000008671 Calycanthus floridus Nutrition 0.000 description 1
- 244000025311 Calycanthus occidentalis Species 0.000 description 1
- 235000008670 Calycanthus occidentalis Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 235000007354 Coix lacryma jobi Nutrition 0.000 description 1
- 244000077995 Coix lacryma jobi Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- 240000005717 Dioscorea alata Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000218218 Ficus <angiosperm> Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029400 Inclusion myopathy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 235000004520 Lindera benzoin Nutrition 0.000 description 1
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 1
- 240000001740 Momordica dioica Species 0.000 description 1
- 235000018365 Momordica dioica Nutrition 0.000 description 1
- 241001263448 Mycetozoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 240000001439 Opuntia Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 241000287420 Pyrus x nivalis Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 241001480055 Quercus mongolica Species 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QKGJFQMGPDVOQE-UHFFFAOYSA-N Sulforaphen Natural products CS(=O)C=CCCN=C=S QKGJFQMGPDVOQE-UHFFFAOYSA-N 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- FRYDSOYOHWGSMD-UHFFFAOYSA-N [C].O Chemical compound [C].O FRYDSOYOHWGSMD-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000002729 catgut Substances 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000036397 gastrointestinal physiology Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000004495 interstitial cells of cajal Anatomy 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000000051 music therapy Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004179 neuropil Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical compound CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000009643 reducing diet Nutrition 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229930186851 sennoside Natural products 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000003384 transverse colon Anatomy 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000003032 wing Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention provides a kind of constipation tailored version clinical nutrition formula, including following component and its parts by weight: 5-10 parts of fat, 20-35 parts of carbohydrate, 45-55 parts of dietary fibers, 0.005-0.02 parts of liposoluble vitamins, 0.008-0.2 parts of water soluble vitamins, 2-6 parts of diet essence, 0.1-8 parts of integration of drinking and medicinal herbs ingredients, 0.1-2 parts of natural plants compounds and 1-7 parts of new resource foods;The present invention also provides the preparation methods of above-mentioned clinical nutrition formula.Constipation tailored version clinical nutrition formula of the invention can alleviate because neuroendocrine disorders, gastroenteritic power deficiency, direct stimulation, enteron aisle form there is the change of non-physiologic, professional Medical Degree, nutrition auxiliary are provided for constipation patient, and constipation patient can be helped to improve body function disorder caused by nutritional deficiency.
Description
Technical field
The present invention relates to clinical nutrition formulation art more particularly to a kind of constipation tailored version clinical nutrition formula and its preparations
Method.
Background technique
Constipation refers to that defecation frequency is reduced, while difficult defecation, excrement are dry and hard.The daily defecation of normal person 1~2 time or 1~2
Day defecation 1 time, defecation is less than 3 times constipation patient weekly, and defecation is laborious, and the scleroma of excrement matter, amount are few.
The pathogenesis of constipation is mainly the following situation:
(1) Intestinal Tract Morphology changes:
It is mainly manifested in and advocates muscle, intramural plexus and Cajal interstitial cells in intestine exception;Gastrointestinal smooth muscle conduct
Its movable final effect device, afunction will lead to colonic activity change;Research confirms that the patient of function of intestinal canal exception deposits
In smooth muscle structure and morphological abnormalities, including different degrees of fibrosis, muscle fiber hyperplasia or atrophy and myocyte's blown-out shot shape
At;For patients with chronic constipation there is also inclusion myopathy, inclusion body is a kind of performance that smooth muscle is degenerated;Chronic constipation person's is straight
There are stove vacuoles and muscle fibre to dissolve for intestines, and muscular layer of mucosa is thinning, the decline of ring longitudinal muscle ratio, and lesion presents and carries out sexual development;
Electrophysiologic study discovery: the enteron aisle of intractable constipation patient prompts non-adrenal gland energy, non-cholinergic neuronal conduction to prolong
It is long, inhibit having a rebound property electrical activity after conduction;Under quiescent condition, when smooth muscle membrane depolarization, it is less to generate action potential;Intestines
Intramural plexus includes meissnar's plexus and myenteric nerve plexus, and patients with chronic constipation is primarily present myenteric nerve plexus change, knot
Enteral myenteric nerve plexus area reduces, and gangliocyte quantity is reduced in neuropile, and proliferation of nerve fibers, the pathology such as disorder change
Become;
The method of immunohistochemistry shows that constipation person myenteric nerve plexus gangliocyte and neuronal cell significantly reduce, nerve
The ratio of spongiocyte increased significantly, and show as depauperation nerve section disease, and meissnar's plexus does not change;
Cajal cell is a kind of special interstitial cell, is generator and the conduction person of Gastroenteric Electrical slow wave, will come from nerve
The stimulation of humoral system is transmitted to effector smooth muscle cell, to adjust the movement of gastrointestinal tract;
Studies have shown that colon ICC quantity is reduced, cellular morphology changes, iuntercellular network structure leads to colonic peristalsis extremely
Frequency deceleration may be the mechanism of constipation of slow-remove type morbidity;In recent years, Calcium overload also intracellular some researches show that ICC
ICC autophagy can be caused, so as to cause the exception of cellular morphology and function, this is extremely related with gastrointestinal tract dynamia.
(2) gastrointestinal regulation peptide changes:
Vasoactive peptide (VIP) is a kind of inhibitory neurotransmitter, plays inhibition adjustment effect to gastrointestinal movement, makes to tie
Bowel movement weakens, and adjusts the fluid metabolism of enteron aisle, and intestinal juice can be made to increase the water content for increasing excrement;
Nitric oxide is very strong inhibitory neurotransmitter, and main by inhibiting L-type calcium channel, activation is big conductance calcium-activated
Potassium channel inhibits smooth muscle contraction;The generation of gastrointestinal tract dyskinesis may be with NO synzyme after zoopery discovery injured spinal cords
The expression of albumen (iNOS) is increased related;
Cholecystokinin (CCK) is a kind of brain intestines for being widely distributed in animal digestive system, maincenter and peripheral neverous system
Peptide discharges in addition to that can directly act on the gastrointestinal tract mucous acetylcholine that may also suppress, the release of VIP, NO is stimulated, to delay
Gastrointestinal smooth muscle is shunk;
Acetylcholine has starting effect in gastrointestinal motility, and cholinergic neuron proportion is maximum between enteron aisle flesh,
Acetylcholine causes the effect of smooth muscle contraction related to its burst size and receptor;
In addition, Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2, serotonin play an important role in intestinal smooth is shunk, the vertical smooth muscle harmony of ring is shunk,
There is positivity to regulate and control meaning intestines peristalsis;However there may be exceptions for these neurotransmitters in patients with chronic constipation, including pass
Matter burst size is insufficient, and reacting cells low to the reactivity of its excitement are reduced etc..
(3) Colon and rectum feeling, motor function and content are abnormal:
The imbalance of brain-gut axis dysfunction of nervous regulation and anal orifice and rectal intestine dissection obstruction are the important originals for leading to Treatment of Outlet Obstruction Type Constipation
Cause;Intestinal mucosa transient receptor potential vanilloid receptor experiences signal in enteric cavity as the receptor on enteron aisle afferent nerve, when
It, which expresses up-regulation, can lead to intestinal motive force obstacle.
(4) psychologic factors influence:
Have scholar it has been suggested that Functional Gastrointestinal Disease concept, it is indicated that gastrointestinal physiology pathological change by heredity, environment
While influence, also by psychosocial influence;
While passive spiritual sensory stimuli expands transverse colon and sigmoid colon in short term, the threshold of feelings is also gradually
It increases, and then cuts down stimulation of the excrement to intestinal wall;
It is presently believed that the generation of IBS irritable bowel syndrome is related to brain-gut axis dysfunction.Functional consitipation (FC) with
IBS-C (constipation-predominant of irritable bowel syndrome) is the common type of constipation, morbidity and mental emotion, the close phase of cerebration
It closes.
(5) nerve immunity reaction intervention:
IBS-C is one kind of constipation, shows as abdominal pain, the discomfort of recurrent exerbation, subtracting with defecation frequency when breaking-out
Less or excrement is dry;It is presently believed that during irritable bowel syndrome morbidity, nerve immunity reaction has certain effect, grinds
When studying carefully discovery IBS-C paresthesia epilepsy, connects and change between Colon mucosa cell, on the one hand show as total colectomy iuntercellular
The quantity for being adhesively joined albumen reduces the disorder of adjoint structure;On the other hand cell tight junction albumen between gut epithelium is shown as
ZO-1 fracture, enteron aisle mechanical barrier is impaired, and the key of this process is the work of enteric nervous member proteinase activated receptors (PAR)
Change;The neuron of activation discharges specific gastrointestinal regulation peptide, successively activates colonic epithelium and mast cell (MC), MC releases group
Amine, protease or prostaglandin etc., act on intestinal epithelial cell, lead to permeability changes;The distribution of Mucosa Biopsy prompt MC
The nerve fibre reacted with immuno positive is neighbouring, MC activation after, release active material act on surrounding endocrine cell and
Nerve fibre makes it discharge a large amount of braingut petides, such as Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 (SP), calcitonin gene-related peptide (CGRP);In MC surrounding tissue
Neuronspecific enolase (NES), SP, 5-HT expression quantity significantly increase, thus it is speculated that this may be with IBS visceral
Related, the active particle that MC is discharged with it plays an important role in Neuroendocrine-immunoregulatory network;The study found that IBS
Microbial reaction and flagellin antibody level increase in different subtype patients serum, in enteron aisle the activation of mucomembranous immune system be
It destroys what gut epithelium barrier function was completed by potential pathogenic microorganism, and proposes that 5-HT will mediate exempt from the such congenital and day after tomorrow
Play a significant role during interacting between epidemic disease response.
(6) other associated effects:
Investigation shows female constipation patient either functional consitipation, chronic constipation or severe constipation, and illness rate is aobvious
It writes and is higher than male;
On the one hand this is related with the intracorporal distinctive progestational hormone of women, and progestational hormone can reduce the convergent force of intestinal muscle,
Inhibit the frequency of intestines peristalsis, and its negative effects is positively correlated with dosage;When hormonal readiness raising or the expression of its receptor height
When, the suppressed effect of colon just becomes apparent from, and constipation symptom is more prominent;
On the other hand, women is in gestation, childbirth etc. in special physiological activity, basin bottom support structure and nerve damage all with
Constipation occurs in close relations.
(7) drug effect
Predominantly opioid drug, depressor, cation drug, antidepressants etc.;
The mechanism that most drugs cause constipation includes two o'clock: 1 inhibits the release of enteron aisle excitatory neurotransmitter, extends colon
Transmission time inhibits intestines peristalsis;On the other hand the character and ingredient that excrement can be changed, cause difficult defecation;Constipation can also be with
Secondary to other diseases, such as metabolic disease, autoimmune disease, the nervous system disease and enteron aisle itself disease etc..
Constipation receives the extensive concern of people, Chinese medicine and doctor trained in Western medicine have carried out greatly constipation as a kind of often hair symptom
Quantifier elimination simultaneously achieves certain progress:
(1) the Chinese medicine progress of constipation:
The sick position of constipation in large intestine, but and liver, spleen, kidney connection is the closest, and pathogenic factor and disorder of emotion, diet are not
Section, the factors such as overstrain is physically weak are related, especially most close with disorder of emotion relationship;Long-term emotional discomfort, anxiety and rage are excessive, cause
Liver dysfunction, functional activity of QI being not smooth, train of thought numbness hinder then abdominal pain;Stagnation of liver qi, catharsis is not normal, and perverse and unreasonable manner multiplies spleen or weakness of the spleen and the stomach, the empty wood of soil
Multiply, the dysfunction of the spleen in transport, cause enteron aisle transporting conduction function not normal and fall ill, depression and stagnation of QI, intestines, which lose to lead to, to drop, stops in waste matter, defecates interior
Knot;Clinically irritable bowel syndrome constipation type is again common with stagnation of QI due to depression of the liver.
Chinese traditional treatment constipation is mainly based on oral medicinal herb, and some researches show that Liumotang treatment constipation type intestines easily swash is invited comprehensive
Simulator sickness tool have a better effect (Liumotang: each 10g of radix aucklandiae, the root of three-nerved spicebush, the dried immature fruit of citron orange, agalloch eaglewood (rear under) 6g, betel nut 9g, raw rhubarb (after
Under) 8g, radix bupleuri 10g, rhizoma cyperi 9g, Fructus meliae toosendan 6g, radish seed 9g, licorice 6g, 1 dose/d, decocting takes juice 400ml, morning and evening each one
Partly warmly take.Continuous treatment 30d is as a treatment course, 90%) treatment total effective rate is;
In addition, there are also colon hydrotherapy, thin fragrant moxibustion, five notes of traditional Chinese music therapy, the methods of catgut implantations at acupoint for Chinese traditional treatment constipation.
The mechanism of Chinese medicine treatment constipation essentially consists in the interaction of Chinese medicine and intestinal microenvironment: the microenvironment of enteron aisle includes
Intestinal flora, intestinal cell and mucous membrane chemical barrier are human body and extraneous the first screen for carrying out substance, energy and information exchange
The interactive interface of human body under the extraneous factors and physio-pathological state such as barrier and diet-drug-pathogenic microorganism, intestines
Road flora is the microflora in people's enteron aisle, is largely focused on Firmicutes, Bacteroidetes, and minority is distributed in mycetozoan
Door, actinomyces door, wart germ door and Fusobacterium door;Major function of the intestinal flora to Human Physiology are as follows: 1, pass through itself enzyme
Promote the non-digestible nutriment of intestinal absorption, 2, promote developing immune system, 3, resist pathogen invasion, 4, promote enteron aisle blood
Pipe generate, 5, protect gut epithelium from damage.Chinese medicine can adjust intestinal microenvironment, and then play the role for the treatment of constipation.
(2) the doctor trained in Western medicine progress of constipation:
General treatment of the doctor trained in Western medicine for constipation are as follows: good living habit is established while treating constipation, on diet
Appropriate to increase dietary fiber, high fiber food helps improvement constipation, eats the food of induced symptom less;Excessive rouge generally should be avoided
The intake of fat and irritable food.Sports appropriate etc. can increase the stimulation to colon, promote gastroenteritic power;Adjust feelings
Thread and behavior keep the life style of good phychology and rule.
Doctor trained in Western medicine mainly includes following several drugs for the drug therapy of constipation:
1, irritant purgative: including phenolphthalein piece, rheum officinale folium sennae, Maren wan, castor oil etc. can directly stimulate enterocinesia,
Reduce moisture absorption;Available effect in short term, is but easy to appear electrolyte disturbance, the adverse reactions such as abdominal pain;Long-time service can be led
It causes patient to aggravate the dependence of cathartic and constipation progressive, takes cathartic for a long time and also result in the complication such as malnutrition, it is at a specified future date
Curative effect is dissatisfied;
2, promote digestive tract power reinforcing medicine: some researches show that the medicines for promoting gastroenteritic power to promote intestinal gas to be discharged, and accelerates enteron aisle fortune
It is dynamic, the treatment of IBS-C patient is had a better effect, Mosapride, by agonist, there is promotion gastroenteritic power as 5-HT4,
The function of stimulating acetylcholine to discharge;Research confirms that Mosapride can relax by expanding about flesh in 5-HT4 receptor enhancing cavy anus
It opens and the rectum of proctectasia excitation is shunk;It can promote Colon Movement simultaneously, it therefore, may be effectively to treatment functional consitipation;
3, antipsychotic drug: research shows that the abdominal distension of IBS patient, abdomen can quickly be eliminated and be improved to the utilization of antidepressants
Bitterly, constipation, anxiety and tense, irritable and depressive symptom.
Chinese patent CN104872638A discloses a kind of constipation non-whole nutritional formula food, uses a variety of through prehydrolysis
Small peptide, the prebiotics, amino acid, carbon hydrate that SBE technology extracts the Chinese medical extract essence of dual-purpose of drug and food, biological enzymolysis extracts
Object, the grease for having healthcare function, multivitamin and minerals the techniques such as are mixed together and are processed into, and can be used as single battalion
Feeding source meets the nutritional need of constipation patient, also acts relax bowel and defecation, nourishing yin to moisten dryness, nourishing liver and kidney, heat-clearing disperse accumulation, promoting
Defaecation, removing toxic substances laxation and anti-the effect for the treatment of constipation.But although the constipation non-whole nutritional formula food of the patent uses type
A considerable number of component is prepared into nutritional formulas, but its main " middle residence that disappears is mended ", " balanced tone " according to Chinese medicine is managed
By in all directions from immune component, neuroendocrine, spiritual nutrition, myoelectricity block not in conjunction with the pathogenesis of constipation
Nutritional support and auxiliary are provided for constipation patient.
Therefore it provides a kind of can interfere the morphologic change of gastrointestinal tract in terms of immune component, divide out of nerve
It secretes aspect the endocrine disturbance mechanism of gastrointestinal tract is adjusted, the body and mind of constipation patient is repaired in terms of spiritual nutrition
It is multiple, will have in terms of the block of myoelectricity to the constipation tailored version clinical nutrition formula interfered that is short of power of gastrointestinal tract
There is important clinical meaning.
Summary of the invention
The technical problems to be solved by the present invention are: in view of the drawbacks of the prior art, it is clinical to provide a kind of constipation tailored version
Nutrient formulation and preparation method thereof can be alleviated because of neuroendocrine disorders, gastroenteritic power deficiency, direct stimulation, enteron aisle
There is the change of non-physiologic in form, provides professional Medical Degree, nutrition auxiliary for constipation patient, and can help constipation patient
Improve body function disorder caused by nutritional deficiency.
The present invention uses following technical scheme to solve above-mentioned technical problem:
The first purpose of the invention is to provide a kind of constipation tailored version clinical nutrition formula, including following component and its again
Measure number: 5-10 parts of fat, 20-35 parts of carbohydrate, 45-55 parts of dietary fibers, 0.005-0.02 parts of liposoluble vitamins,
0.008-0.2 parts of water soluble vitamins, 2-6 parts of diet essence, 0.1-8 parts of integration of drinking and medicinal herbs ingredients, 0.1-2 parts of natural plants chemical combination
Object and 1-7 parts of new resource foods;
Wherein, the integration of drinking and medicinal herbs ingredient includes cassia seed, endothelium corneum gigeriae galli, dandelion, Poria cocos, semen ziziphi spinosae, radish seed, Yu Li
At least one of benevolence, peach kernel, Chinese yam, oyster, black pepper, Radix Glycyrrhizae, the sophora bud, peppermint, lily, dried orange peel, root of Dahurain angelica;
Wherein, the new resource food includes first milk basic protein, γ-aminobutyric acid, chitosan oligosaccharide, eucommia Bark male flower, the leaf of bamboo
Flavones, casein phosphopeptide, avenabeta glucosan, yeast beta-dextran, newborn mineral salt, pueraria root powder, Rosa roxburghii Tratt, xylo-oligosaccharide, circle
At least one of luxuriant isapgol husk, Noni puree, lactobacillus.
In order to optimize above-mentioned technical solution, the technical measures that the present invention takes further include:
Further, the fat includes saturated fatty acid, polyunsaturated fatty acid, monounsaturated fatty acids, OPO structure
At least one of rouge, DHA, EPA, ARA, phosphatide.
Further, the fat includes olive oil;Further, the parts by weight of the olive oil are 5-6 parts.
Further, the carbohydrate includes fructose, rock sugar, lactose, maltodextrin, tapioca, resistant starch
At least one of.
Further, the carbohydrate includes maltodextrin;Further, the parts by weight of the maltodextrin
It is 20-30 parts;More preferably 22-25 parts.
Further, the dietary fiber includes inulin, konjaku flour, galactooligosaccharide, oligofructose, oligomeric different malt
At least one of sugar, soybean polyoses, cyclodextrin, resistant dextrin, soybean fiber.
Further, the dietary fiber includes inulin and galactooligosaccharide;Further, the dietary fiber includes
5-10 parts of inulin and 5-10 parts of galactooligosaccharides.
Further, the dietary fiber is resistant dextrin, inulin and galactooligosaccharide;Further, the diet
The parts by weight of each component in fiber are as follows: 25-45 parts of resistant dextrin, 5-10 parts of inulin, 5-10 parts of galactooligosaccharide;More preferably
For the parts by weight of each component in the dietary fiber are as follows: 40-45 parts of resistant dextrin, 5-8 parts of inulin, galactooligosaccharide 5-8
Part.
Further, the liposoluble vitamin includes vitamin A, beta carotene, vitamin D3, vitamin E, dimension life
Plain K1At least one of.
It further, include 0.005-0.01 parts of vitamin Es in the liposoluble vitamin.
Further, the water soluble vitamin includes vitamin B1, vitamin B2, vitamin B6, vitamin B12, dimension life
At least one of plain C, pantothenic acid, folic acid, niacin, choline, inositol, biotin.
Further, the water soluble vitamin includes vitamin B1, vitamin B2, vitamin B6, vitamin B12, dimension life
Plain C.
Further, each component and its parts by weight in the water soluble vitamin are as follows: vitamin B10.001-0.005
Part, vitamin B20.001-0.005 parts, vitamin B60.001-0.005 parts, vitamin B120.0000001-0.000002 parts,
0.1-0.5 parts of vitamin C.
Further, the diet essence includes cereal, beans, potato, greengrocery, Homonemeae, nut-seed class, fishes and shrimps
At least one of class, poultry meat, fruits;Wherein, the cereal include rice meal, millet flour, black rice flour, coixlacrymajobi powder,
At least one of corn flour, wheat germ powder, oatmeal, buckwheat;The beans include peameal, mung bean flour, black bean powder,
At least one of red bean powder, soy meal;The potato is mainly made of common yam rhizome powder, and the greengrocery includes carrot meal, white trailing plants
At least one of Bu Fen, pumpkin powder, spinach powder, tomato meal, broccoli powder, balsam pear powder;The Homonemeae includes mushroom powder, sea
Band at least one of powder, tremella powder;The nut-seed class includes at least one of pumpkin seed powder and lotus nut starch;The fish
Shrimps include at least one of salmon powder and cod meal;The poultry meat chicken meal, powdered beef, in pig kidney powder at least
It is a kind of;The fruits include red date powder, longan powder, apple powder, cherry powder, citrus powder, pyrus nivalis powder, in Opuntia ficus' powder
It is at least one.
Further, the diet essence includes at least oatmeal and white radish powder;Further, the oatmeal
Parts by weight are 1-3 parts, and the parts by weight of the white radish powder are 1-3 parts.
Further, the integration of drinking and medicinal herbs ingredient includes cassia seed, endothelium corneum gigeriae galli, radish seed, dandelion, brush-cherry seed, peach kernel.
Further, the integration of drinking and medicinal herbs ingredient further includes the sophora bud, peppermint, semen ziziphi spinosae, lily, dried orange peel, the root of Dahurain angelica.
Further, cassia seed in the integration of drinking and medicinal herbs ingredient, endothelium corneum gigeriae galli, radish seed, dandelion, brush-cherry seed, peach kernel
Parts by weight are as follows: 0.1-1 parts of cassia seed, 0.1-1 parts of endothelium corneum gigeriae galli, 0.1-1 parts of radish seed, 0.1-1 parts of dandelion, brush-cherry seed 0.1-
1 part, 0.1-1 parts of peach kernel.
Further, in the integration of drinking and medicinal herbs ingredient sophora bud, peppermint, semen ziziphi spinosae, lily, dried orange peel, the root of Dahurain angelica parts by weight
Are as follows: 0.1-1 parts of the sophora bud, 0.1-1 parts of peppermint, 0.1-1 parts of semen ziziphi spinosae, 0.1-1 parts of lily, 0.1-1 parts of dried orange peel, 0.1-1 parts of the root of Dahurain angelica.
Further, the natural plants compound includes L-carnitine, Glucosamine, oligofructose, lutein, plant
At least one of object sterol, lycopene, resveratrol, allicin.
Further, the natural plants compound includes L-carnitine;Further, the weight of the L-carnitine
Number is 0.1-1 parts.
Further, the lactobacillus in the new resource food includes lactobacillus acidophilus, lactobacillus plantarum, rhamnose cream bar
At least one of bacterium.
Further, the new resource food includes chitosan oligosaccharide, circle luxuriant isapgol husk, Noni puree, lactobacillus acidophilus, plant
Object lactobacillus, Lactobacillus rhamnosus, avenabeta glucosan.
Further, chitosan oligosaccharide, circle luxuriant isapgol husk, Noni puree, lactobacillus acidophilus, plant in the new resource food
Object lactobacillus, Lactobacillus rhamnosus, avenabeta glucosan parts by weight are as follows: the luxuriant isapgol husk 3-5 of chitosan oligosaccharide 0.1-0.5, circle
Part, 0.1-1 parts of Noni puree, 0.01-0.03 parts of lactobacillus acidophilus, 0.01-0.02 parts of lactobacillus plantarum, Lactobacillus rhamnosus
0.01-0.02 parts, 0.1-1 parts of avenabeta glucosan.
A second object of the present invention is to provide a kind of preparation methods of above-mentioned constipation tailored version clinical nutrition formula, including
Following steps:
Step 1, fat powder is prepared;
Step 2, integration of drinking and medicinal herbs ingredient and vitamin are prepared into powder particle diameter is 60~80 mesh powders;
Step 3, by the carbohydrate of predetermined weight, dietary fiber, diet essence, natural plants compound and new money
Source food is prepared into the powder that powder particle diameter is 150~250 μm respectively;
Step 4, powder obtained by step 1~3 is sequentially added into mixing machine and is uniformly mixed obtained formula mixture, passed through
It is spare after sterilization processing;
Step 5, the formula mixture is prepared into nutrient powder, nutrition emulsion, capsule, tablet, pill or oral solution
At least one of;
Wherein, the sequence of step 1~3 can be replaced mutually.
In order to optimize above-mentioned preparation method, the technical measures that the present invention takes further include:
Further, in step 1 fat powder preparation method the following steps are included:
1) it prepares wall material aqueous solution: maltodextrin 8g, Arabic gum 0.2g, water 20mL being taken to stir evenly;
2) 0.1g (total solid concentration is 0.2%) is taken uniformly to be dissolved in the olive oil of 6.7mL monoglyceride;
3) 0.1g (total solid concentration is 0.2%) is taken uniformly to be dissolved in the wall material aqueous solution Tween 80;
4) the wall material aqueous solution of the mixed plant grease and addition Over emulsfication agent Tween 80 of Over emulsfication agent monoglyceride will be added
It is sufficiently mixed, obtains mixed solution;
5) stabilizer agar 0.1g (total solid concentration is 0.2%) is added after the mixed solution, is settled to water
High speed dispersion 2 minutes under 200mL (total solid concentration is 25%), 20000r/min, emulsion is obtained;
6) by the emulsion at homogenization pressure 25MPa, homogeneous 3 times, 5 minutes every time, homogeneous emulsion is obtained;
7) the homogeneous emulsion is spray-dried, inlet air temperature is 195 DEG C, and leaving air temp is 80 DEG C, is collected
To fat powder.
Further, in the step 2 preparation method of integration of drinking and medicinal herbs component powders the following steps are included: using pulverizer
The raw material of predetermined weight number is crushed, the raw material of crushing is placed in container, 3~8 that weight is raw material weight are added
Water again, carries out immersion 3~4 hours, then carries out 30~60min of decoction to soak, and filtering removal raw material leaves and takes decoction
Liquid is spray-dried decoction liquor, prepares integration of drinking and medicinal herbs component powders with 60~80 meshes point.
Further, in the step 2 preparation method of vitamin powder the following steps are included: by predetermined weight number
Liposoluble vitamin selects carragheen, Arabic gum as wall material as core material, carries out 2 emulsifying homogeneous processing under high pressure,
The emulsifying homogeneous time is 10~15min, is then instantaneously dried by spraying, prepares liposoluble vitamin powder with 60~80 meshes point
End;Using the water soluble vitamin of predetermined weight number as core material, selects maltodextrin, lipoprotein as wall material, is uniformly mixed,
It is spraying instantaneous dry, water soluble vitamin powder is prepared with 60~80 meshes point.
Further, optionally increase suitable food thickening agent and food additives in the step 5.
Further, the food thickening agent includes guar gum, xanthan gum, locust bean gum, konjac glucomannan, pectin, carragheen, fine jade
At least one of rouge, gelatin, Arabic gum, the food additives include Aspartame, edible essence fragrance, in brown sugar
It is at least one.
Further, the food thickening agent be guar gum, carragheen, Arabic gum, the food additives be Ah
This Ba Tian, edible essence fragrance.
In the present invention using including cassia seed, endothelium corneum gigeriae galli, radish seed, dandelion, brush-cherry seed, peach kernel integration of drinking and medicinal herbs at
Point, there is toxin-expelling intestine-moistening after mentioned component compatibility synergy, promote intestines peristalsis, enhancing gastro-intestinal digestion ability, enhancing immune function
Effect, facilitate restore gastrointestinal tract form, adjust gastrointestinal tract endocrine disturbance.
The rheum emodin that cassia seed contains can help heat-clearing, ease constipation, the side that the junk of human body is effectively passed through defecation
Formula excretes, cassia seed nourishing Yin and clearing heat, and, toxin accumulation unsmooth for defecation caused by interior heat also has good remission effect;
Endothelium corneum gigeriae galli sugariness is puckery, puts down, nontoxic, enters spleen, stomach, small intestine, wing moon bright four and passes through, be good at digestion gathered food, strengthening the spleen and stomach, it is puckery it is glutinous only
Lose, change hard product and disappear calculus, can be used for dyspepsia, vomiting dysentery, infantile malnutrition, the enuresis, spermatorrhea, the puckery pain of urolithiasis, distension of gallbladder, hypochondriac pain,
Canker sore is quenched one's thirst, the proliferation of mammary gland, amenorrhoea, the diseases such as fibroid;Modern research shows that endothelium corneum gigeriae galli is mainly by albumen texture
At main component has gastric hormone, keratin like protein, pepsin, and contains the amino such as vitamin, glutamic acid and asparatate
Acid has the ability for increasing gastric secretion, gastro-intestinal digestion, can accelerate the rate of evacuation of stomach, is improving blood lipid, hemorheology
There is potential bioactivity with myocardial preservation aspect;
Radish seed is containing raphanin, sinapine, fat oil, cupreol, carbohydrate and a variety of amino acid, vitamin etc., grease
The effect for itself having yin-nourishing QI invigorating, relax bowel and defecation, has better effect to habitual constipation person;Animal experiments show that radish seed water
Decoction can be such that isolated rabbit intestines shrinkage amplitude increases, and Guinea pig Gastric shrinkage amplitude can be made to increase;Chinese medicine thinks that radish seed has lower gas, dispels
The function of phlegm, promoting digestion and removing indigestion;
Dandelion property bitter sweet is trembled with fear, and liver, stomach meridian are entered, and has the benefits of clearing heat and detoxicating, diuresis dissipating bind;" dandelion exempts from mouse
Hypoimmunity mice can be improved in discovery, dandelion in the adjustment effect of epidemic disease function " (Yu Xinhui is published in Chinese Medicine guide)
Immune function has the function of enhancing the formation of the phagocytosis system, hemolysis plaque of the macrophage of body;
Brush-cherry seed plays the role of significantly promoting enterocinesia, and the influence to constipation is the most significant with constipation type anti-constipation effect;
Brush-cherry seed glucoside contained by brush-cherry seed has strong discharge function to experiment, and discharge function mechanism is similar to Sennosides, category large intestine
Purgatives, but also have proof, brush-cherry seed water extract and its fat oil have extremely significant promotion intestinal motility effect to intragastric administration on mice,
50% water decoction of brush-cherry seed seed can be obviously shortened constipation type, and just close model mice defecation time, defecation frequency obviously increase;
Peach kernel has the function of relax bowel and defecation, is particularly suitable for old physically weak constipation patient, and Chinese medicine thinks that peach kernel has broken
Blood become silted up, moisturizing dryness and lubricating intestine, can ease pain, anti-inflammatory, removing toxic substances, defaecation the effect of.
Using including chitosan oligosaccharide, circle luxuriant isapgol husk, Noni puree, lactobacillus acidophilus, lactobacillus plantarum, mouse in the present invention
The new resource food of Lee's sugar lactobacillus, avenabeta glucosan has after mentioned component compatibility synergy and adjusts intestinal flora, promotes intestines
Road wriggling, relax bowel and defecation, the function of alleviating headache, strengthen immunity help to improve stomach and intestine in terms of the block of myoelectricity
Road is short of power, and helps to repair damaged cell tissue, improves gastrointestinal tract form, helps to alleviate direct stimulation to enteron aisle
The influence of function.
Chitosan oligosaccharide is the dietary fiber of animality, has and promotes profitable strain (such as Bacillus acidi lactici), inhibits pernicious bacteria
The effect of breeding;Chitosan oligosaccharide can promote the wriggling of enteron aisle as cationic animal origin, remove the stool and toxin of big enteral, from
And adjust gastrointestinal function effectively;
The main component of circle bud isapgol husk is a kind of soluble polysaccharide, is araboxylan, it can absorb rapidly water,
G., jelly-like thick liquid is formed, when we take circle bud isapgol husk aqueous solution, gel group can be formed in enteron aisle, it can be tieed up
The moisture and pliability of excrement are held, improves the lubricating condition of excrement and intestinal wall, stimulation intestinal wall generates reflex contraction effect, and promotees
Into the emptying for even accelerating excrement;Therefore, the luxuriant isapgol husk of circle just is used to moisten as natural laxative since ancient times
Intestines defaecation;
Noni puree is rich in vitamin C, can help to repair damaged cell tissue, be natural analgesic, help to alleviate
Obstinate headache and not any side effect can stimulate digestion as agent help of coming down in torrents, treat constipation and gastric acid refluence
Equal enterogastric diseases, and Noni puree antioxidant also rich in;
Lactobacillus acidophilus can effectively inhibit harmful bacteria growth, gastrointestinal tract, nutrition gastrointestinal tract is protected to repair the screen of gastrointestinal tract
Barrier and the flora for adjusting gastrointestinal tract;
Lactobacillus plantarum has immunoloregulation function, helps to reduce cholesterolemia and prevents cardiovascular disease, maintains stomach and intestine
Colony balance, promotion absorption of nutrient ingredients, alleviation lactose intolerance, the formation for inhibiting tumour cell etc. in road;
Lactobacillus rhamnosus, which has, balances and improves gastrointestinal function, and strengthen immunity promotes Bifidobacterium and acidophilus cream
Bacillus growth, prevention and treatment diarrhea, allergy, the function of toxin expelling;
Avenabeta glucosan cannot hydrolyze in small intestine, and degradation and the substrate as bacterial fermentation in large intestine, fermentation
Short chain fatty acids, especially butyric acid are generated, function of intestinal canal is beneficial to, mono- glucan of oat p can make double in mouse intestinal and excrement
Discrimination bacillus and Bacillus acidi lactici increment, and reduce the quantity of Escherichia coli, therefore oat beta-glucan also has improvement function of intestinal canal,
Promote the increment of intestinal beneficial bacterium;For beta glucan as a kind of nonspecific immunomodulator, it can not only activate T, B lymph
The immunocytes such as cell, macrophage, natural killer cells, moreover it is possible to promote cell factor to generate, activating complement system promotes anti-
Body generates, and plays various adjustment effects to immune system.
The present invention by adopting the above technical scheme, compared with prior art, has the following technical effect that
1) galactooligosaccharide is added, galactooligosaccharide is strongest double qi proliferation factors, and effect includes blocking pathogen
In the adherency and promotion intellectual development etc. of intestinal mucosa renal function.
2) inulin is added, inulin helps to control blood glucose, reduces blood lipid, promotes mineral absorption, adjusts enteric microorganism
Flora improves intestinal health, and the generation for preventing constipation, inhibiting toxic tunning protects liver, prevents colon cancer, anti-constipation
And treatment obesity diet fiber reduces food in the residence time of stomach and intestine, and increases excrement amount, effectively treats constipation;Its
Antiobesity action is the viscosity for improving content, reduces food and enters the speed of small intestine from stomach, to reduce hunger, reduces food
Food ration;There is a small amount of 2-9 oligofructose in inulin, studies have shown that oligofructose can make brain nervous cell trophic factors
Expression increases, and has good protective effect to the neuron harm of cortisone induction, has good antidepressant effect.
3) 0.005-0.01 parts of vitamin Es are added, vitamin E has the effect of convergence, softening hard masses, and anal canal can be made to be in longer
Time relaxed state lowers the pressure in anal canal, sphincterismus is enable to alleviate, and promotes anus blood circulation, improves
Nutrition and Metabolism in anus.
4) it also added on the basis of above-mentioned integration of drinking and medicinal herbs is at subassembly including the sophora bud, peppermint, semen ziziphi spinosae, lily, old
The integration of drinking and medicinal herbs ingredient of skin, the root of Dahurain angelica: sophora bud bitter cold nature returns liver, large intestine channel, and the sophora bud cold in nature can increase the lubrication of enteron aisle
Degree, plays the role of defaecation, and the sophora bud enters large intestine channel, can act on large intestine, plays the role of promoting intestinal health, the and " sophora bud
Mongolian oak in protective effect research of the middle Quercetin to anxiety model mice " (Nie Zhongfu is published in " China Dispensary ") discovery sophora bud
Pi Suneng has angst resistance effect to mouse as anxiolytic diazepam, and Antianxiety Activity may be with increase intracerebral
GANA, Glu content are related;The peppermint oil contained in peppermint has volatility, in vivo have promoting the circulation of qi effect, can soothing liver-qi stagnation,
It can be used for treating the diseases such as stagnation of QI due to depression of the liver, distending pain in the chest and hypochondrium;Semen ziziphi spinosae has the effect of antitoxic heart-soothing and sedative, calming the liver qi-regulating, particularly suitable nerve
Weak, horrified to much dream crowd eats, and also has effects that nourishing blood and tranquilization, is relatively specific for palpitaition caused by the insufficiency of heart and spleen, gas
It is short, insomnia and dreamful sleep, the diseases such as dysphoria and insomnia;It is lily cold nature, sweet in flavor, there are moistening lung, cough-relieving, heat-clearing, removing toxic substances, reason spleen stomach invigorating, dampness removing
Disperse accumulation, antitoxic heart-soothing and sedative promote blood circulation and other effects;Orange peel enters spleen, stomach meridian, is good at promoting the circulation of qi, can treat the disease of the taste stagnation of the circulation of vital energy, such as
Abdominal fullness and distention or abdominal pain, deficiency of food receive the malaise symptoms such as poor, indigestion, chest diaphragm feeling of fullness;Root of Dahurain angelica acrid flavour, it is warm-natured, return lung, spleen, stomach,
Large intestine channel has the benefits of expelling pathogenic wind from the body surface, eliminating cold to stop pain, dehumidifying sensible, detumescence and apocenosis, and modern pharmacological research proves, the root of Dahurain angelica in addition to
Has the effects that antipyretic, analgesia, anti-inflammatory, moreover it is possible to improve local blood circulation, eliminate pigment excess accumulation in the tissue, promote skin
Skin cell metabolism, and then have the function that beauty, clinic is common control anemofrigid cold, headache, toothache, pain in the supra-orbital bone, nasosinusitis,
Intestines wind anal fistula, leukorrhea with reddish discharge, ulcer sores, venomous snake bite etc.;After mentioned component compatibility synergy, peomote intestinal health,
Enhance gastro-intestinal digestion ability, also there is the benefits of antianxiety, antitoxic heart-soothing and sedative, facilitate gastrointestinal tract caused by reducing spiritual sensory stimuli
Dysfunction repairs the body and mind of constipation patient in terms of spiritual nutrition, facilitates in terms of neuroendocrine to stomach and intestine
The endocrine disturbance mechanism in road is adjusted.
The present invention by select rational proportion basal nutrient element, while add have toxin-expelling intestine-moistening, promote intestines peristalsis,
Enhance gastro-intestinal digestion ability, alleviate gastrointestinal dysfunction, antitoxic heart-soothing and sedative, enhance the dietary fiber of immune function, diet essence,
The special dietaries substances such as integration of drinking and medicinal herbs ingredient, natural plants compound and new resource food, and adjust its proportion and sought with basis
It supports element and carries out compatibility synergy, the constipation tailored version clinical nutrition formula of the invention made is easier to be absorbed by constipation patient, thus
The effect of giving full play to each component provides professional Medical Degree, nutrition auxiliary for constipation patient, and constipation patient is helped to improve battalion
Support body function disorder caused by lacking.
Specific embodiment
The present invention provides a kind of constipation tailored version clinical nutrition formulas comprising following component and its parts by weight: 5-
10 parts of fat, 20-35 parts of carbohydrate, 45-55 parts of dietary fibers, 0.005-0.02 parts of liposoluble vitamins, 0.008-0.2
Part water soluble vitamin, 2-6 parts of diet essence, 0.1-8 parts of integration of drinking and medicinal herbs ingredients, 0.1-2 parts of natural plants compounds and 1-7
Part new resource food;Wherein, the integration of drinking and medicinal herbs ingredient includes cassia seed, endothelium corneum gigeriae galli, dandelion, Poria cocos, semen ziziphi spinosae, radish
At least one of son, brush-cherry seed, peach kernel, Chinese yam, oyster, black pepper, Radix Glycyrrhizae, the sophora bud, peppermint, lily, dried orange peel, root of Dahurain angelica;
Wherein, the new resource food includes first milk basic protein, γ-aminobutyric acid, chitosan oligosaccharide, eucommia Bark male flower, bamboo-leaves flavones, junket egg
White phosphoeptide, avenabeta glucosan, yeast beta-dextran, newborn mineral salt, pueraria root powder, Rosa roxburghii Tratt, xylo-oligosaccharide, the luxuriant semen plantaginis of circle
At least one of shell, Noni puree, lactobacillus.
The present invention is described in more detail below by specific embodiment, for a better understanding of the present invention,
But following embodiments are not intended to limit the scope of the invention.
Embodiment 1
Constipation tailored version clinical nutrition formula of the present invention includes olive oil 6g, maltodextrin 25g, resistant dextrin
40g, inulin 5g, galactooligosaccharide 5g, vitamin E 0.009g, vitamin B10.001g, vitamin B20.001g, vitamin
B60.001g, vitamin B120.0000017g, vitamin C 0.16g, oatmeal 3g, white radish powder 3g, cassia seed 1g, endothelium corneum gigeriae galli
The luxuriant Cillium 3g of 1g, radish seed 1g, dandelion 1g, brush-cherry seed 1g, peach kernel 1g, L-carnitine 0.8g, circle, Noni fruit starch
1g, avenabeta glucosan 1g, chitosan oligosaccharide 0.5g, lactobacillus acidophilus 0.022g, Lactobacillus rhamnosus 0.020g, lactobacillus plantarum
0.016g。
Embodiment 2
Constipation tailored version clinical nutrition formula of the present invention includes olive oil 6g, maltodextrin 34.4g, resistant dextrin
40g, inulin 5g, galactooligosaccharide 5g, vitamin E 0.009g, vitamin B10.001g, vitamin B20.001g, vitamin
B60.001g, vitamin B120.0000017g, vitamin C 0.16g, oatmeal 1g, white radish powder 1g, cassia seed 0.1g, in chicken
The luxuriant Cillium of golden 0.1g, radish seed 0.1g, dandelion 0.1g, brush-cherry seed 0.1g, peach kernel 0.1g, L-carnitine 0.8g, circle
3g, Noni fruit starch 1g, avenabeta glucosan 1g, chitosan oligosaccharide 0.5g lactobacillus acidophilus 0.022g, Lactobacillus rhamnosus 0.020g,
Lactobacillus plantarum 0.016g.
Embodiment 3
Constipation tailored version clinical nutrition formula of the present invention includes olive oil 6g, maltodextrin 34.4g, resistant dextrin
42.3g, inulin 5g, galactooligosaccharide 5g, vitamin E 0.009g, vitamin B10.001g, vitamin B20.001g, vitamin
B60.001g, vitamin B120.0000017g, vitamin C 0.16g, oatmeal 1g, white radish powder 1g, cassia seed 0.1g, in chicken
The luxuriant Cillium of golden 0.1g, radish seed 0.1g, dandelion 0.1g, brush-cherry seed 0.1g, peach kernel 0.1g, L-carnitine 0.8g, circle
3g, Noni fruit starch 0.1g, avenabeta glucosan 0.1g, chitosan oligosaccharide 0.1g, lactobacillus acidophilus 0.01g, Lactobacillus rhamnosus
0.01g, lactobacillus plantarum 0.01g.
Embodiment 4
Constipation tailored version clinical nutrition formula of the present invention includes olive oil 6g, maltodextrin 25g, resistant dextrin
40g, inulin 5g, galactooligosaccharide 5g, vitamin E 0.009g, vitamin B10.001g, vitamin B20.001g, vitamin
B60.001g, vitamin B120.0000017g, vitamin C 0.16g, oatmeal 3g, white radish powder 3g, cassia seed 1g, endothelium corneum gigeriae galli
It is 1g, radish seed 1g, dandelion 1g, brush-cherry seed 1g, peach kernel 1g, sophora bud 1g, peppermint 1g, semen ziziphi spinosae 1g, lily 1g, dried orange peel 1g, white
It is the luxuriant Cillium 3g of root of Dahurian angelica 1g, L-carnitine 0.8g, circle, Noni fruit starch 1g, avenabeta glucosan 1g, chitosan oligosaccharide 0.5g, thermophilic
Lactobacillus lactis 0.022g, Lactobacillus rhamnosus 0.020g, lactobacillus plantarum 0.016g.
Embodiment 5
Constipation tailored version clinical nutrition formula of the present invention includes olive oil 6g, maltodextrin 25g, resistant dextrin
40g, inulin 5g, galactooligosaccharide 5g, vitamin E 0.009g, vitamin B10.001g, vitamin B20.001g, vitamin
B60.001g, vitamin B120.0000017g, vitamin C 0.16g, oatmeal 3g, white radish powder 3g, cassia seed 1g, endothelium corneum gigeriae galli
The luxuriant Cillium 3g of 1g, Poria cocos 1g, dandelion 1g, Chinese yam 1g, Radix Glycyrrhizae 1g, L-carnitine 0.8g, circle, Noni fruit starch 1g,
γ-aminobutyric acid 1g, chitosan oligosaccharide 0.5g, lactobacillus acidophilus 0.022g, Lactobacillus rhamnosus 0.020g.
Embodiment 6
A kind of constipation tailored version clinical nutrition formula as described in 1~embodiment of embodiment 5 the preparation method is as follows:
1) fat powder is prepared;
A) prepare wall material aqueous solution: taking maltodextrin 8g, Arabic gum 0.2g, water 20mL to stir evenly, (side of having ready conditions adds
Hot side is stirred to 60 DEG C, is cooled to room temperature after being kept for 30 minutes);
B) 0.1g (total solid concentration is 0.2%) is taken uniformly to be dissolved in the olive oil of 6.7mL monoglyceride;
C) 0.1g (total solid concentration is 0.2%) is taken uniformly to be dissolved in the wall material aqueous solution Tween 80;
D) the wall material aqueous solution of the mixed plant grease and addition Over emulsfication agent Tween 80 of Over emulsfication agent monoglyceride will be added
It is sufficiently mixed, obtains mixed solution;
E) stabilizer agar 0.1g (total solid concentration is 0.2%) is added after the mixed solution, is settled to water
High speed dispersion 2 minutes under 200mL (total solid concentration is 25%), 20000r/min, emulsion is obtained;
F) by the emulsion at homogenization pressure 25MPa, homogeneous 3 times, 5 minutes every time, homogeneous emulsion is obtained;
G) the homogeneous emulsion is spray-dried, inlet air temperature is 195 DEG C, and leaving air temp is 80 DEG C, is collected
To fat powder;
2) integration of drinking and medicinal herbs component powders are prepared: being crushed, will be crushed using raw material of the pulverizer to predetermined weight number
Raw material be placed in container, be added weight be raw material weight 3~8 times of water, immersion is carried out 3~4 hours, then to soak
30~60min of decoction is carried out, filtering removal raw material is left and taken decoction liquor, is spray-dried to decoction liquor, with 60~80 meshes point
Prepare integration of drinking and medicinal herbs component powders;
3) prepare vitamin powder: using the liposoluble vitamin of predetermined weight number as core material, select carragheen, I
Primary glue carries out 2 emulsifying homogeneous processing as wall material under high pressure, and the emulsifying homogeneous time is 10~15min, is then sprayed
It is instantaneous dry, liposoluble vitamin powder is prepared with 60~80 meshes point;Using the water soluble vitamin of predetermined weight number as
Core material is selected maltodextrin, lipoprotein as wall material, is uniformly mixed, spraying instantaneous dry, is prepared with 60~80 meshes point water-soluble
Property vitamin powder;
4) carbohydrate of predetermined weight, dietary fiber, diet essence, natural plants compound and new resources are eaten
Product are prepared into the powder that powder particle diameter is 150~250 μm respectively;
5) mixing machine that powder obtained by step 1~4 sequentially adds cone-type mixer or other forms is uniformly mixed
Formula mixture is made, it is spare after sterilization processing;
6) formula mixture made from step 5) is prepared by nutrient powder, nutrition emulsion, capsule according to conventional technical means
At least one of agent, tablet, pill or oral solution.
In step 6), optionally increase suitable food thickening agent and food additives.The food thickening agent
It is described at least one of guar gum, xanthan gum, locust bean gum, konjac glucomannan, pectin, carragheen, agar, gelatin, Arabic gum
Food additives are at least one of Aspartame, edible essence fragrance, brown sugar;More preferable carragheen, Arabic gum, Guar
Glue, Aspartame, edible essence fragrance.
Aforesaid operations step is both needed to carry out under the protection of inert gas, such as nitrogen, argon gas, helium etc., to prevent from producing
The danger of green powder explosion.
It can be prepared into the classifications such as powdery, graininess, capsule shape, tablet shape, beverage according to the formula.
Embodiment 7
The present embodiment is verifying embodiment.
This verifying embodiment controls mice with constipation by verifying constipation tailored version clinical nutrition formula of the present invention
Treatment is acted on to verify its influence to constipation patient.The present embodiment using embodiment 1-5 formula preparation nutrient powder and under
State comparative example:
Control group: the suspension containing 2% india ink that distilled water is made into;
Experimental group 1: the nutrient powder prepared using the nutrient formulation of embodiment 1, and dilute dissolution and be made into containing 2% india ink
Suspension;
Experimental group 2: the nutrient powder prepared using the nutrient formulation of embodiment 2, and dilute dissolution and be made into containing 2% india ink
Suspension;
Experimental group 3: the nutrient powder prepared using the nutrient formulation of embodiment 3, and dilute dissolution and be made into containing 2% india ink
Suspension;
Experimental group 4: the nutrient powder prepared using the nutrient formulation of embodiment 4, and dilute dissolution and be made into containing 2% india ink
Suspension;
Experimental group 5: the nutrient powder prepared using the nutrient formulation of embodiment 5, and dilute dissolution and be made into containing 2% india ink
Suspension;
Experimental group 6: it using the nutrient powder prepared after deletion new resource food in the nutrient formulation of embodiment 1, and dilutes molten
Solution is made into the suspension containing 2% india ink.
Mice with constipation model is prepared using Kunming mouse, takes Kunming mouse totally 70, weight 25-30g, adaptability is raised
It supports after a week, disposable stomach-filling compound diphenoxylate 40mg/kg, mouse may occur in which that defecation grain number is reduced, and defecation time extends
Phenomena such as, establish mice with constipation model.
Above-mentioned mice with constipation model is divided into 7 groups at random, and every group 10, respectively as control group, experimental group 1, experimental group
2, experimental group 3, experimental group 4, experimental group 5, experimental group 6, the corresponding distilled water of every group of difference stomach-filling each group or nutritional agents fill daily
Weishang noon, afternoon are each primary, and by 5mL/100g, (nutrient powder amount corresponding to experimental group 1- experimental group 6 is every milli to each stomach-filling amount
Rise in nutritional agents and dissolve 0.1g-0.11g), continuous gavage 7d.Give each group mouse free diet during test.
Observe and record total grain number that discharge melena in the time and 4h of melena is discharged in every mouse for the first time;
Blank group in 7d, control group, experimental group 1, experimental group 2, experimental group 3, experimental group 4, experimental group 5, reality are collected respectively
The defecation of the mouse of group 6 is tested, excrement calculates dejecta moisture after 90 DEG C of dry 10h;
The results are shown in Table 1 for it:
Influence of the constipation tailored version clinical nutrition formula of the present invention of table 1 to mice with constipation defecation
It can see by the result of Tables 1 and 2, experimental group 1-6 can be obviously promoted mice with constipation row compared to control group
Just, dejecta moisture is improved.It is obvious positive to illustrate that constipation tailored version clinical nutrition formula of the invention has mice with constipation
It influences.
as can be seen from the above embodiment ,the components of the constipation-specific clinical nutrition formula of the present invention cooperate with each other ,so that
Secret patient provides nutritional support rationally, comprehensively, balanced, to improve the physical condition of constipation patient, keep patient body quality
Stabilization, booster immunization responsibility, while add dietary fiber, diet essence, integration of drinking and medicinal herbs ingredient, natural plants chemical combination
The special dietaries such as object and new resource food substance with have toxin-expelling intestine-moistening, promote intestines peristalsis, enhancing gastro-intestinal digestion ability,
Alleviate gastrointestinal dysfunction, antitoxic heart-soothing and sedative, enhancing immune function, helps to change the form of gastrointestinal tract in terms of immune component
Change is interfered, and the endocrine disturbance mechanism of gastrointestinal tract is adjusted in terms of neuroendocrine, right in terms of spiritual nutrition
The body and mind of constipation patient is repaired, and is interfered in terms of the block of myoelectricity being short of power for gastrointestinal tract, Neng Gouhuan
Solution is because of the change of non-physiologic occurs in the form of neuroendocrine disorders, gastroenteritic power deficiency, direct stimulation, enteron aisle, for just
Secret patient provides professional Medical Degree, nutrition auxiliary, and constipation patient can be helped to improve body function caused by nutritional deficiency
Disorder.
Specific embodiments of the present invention are described in detail above, but it is only used as example, the present invention is not intended to limit
In particular embodiments described above.To those skilled in the art, it any equivalent modifications to the practical progress and replaces
In generation, is also all among scope of the invention.Therefore, without departing from the spirit and scope of the invention made by equal transformation and repair
Change, all should be contained within the scope of the invention.
Claims (10)
1. a kind of constipation tailored version clinical nutrition formula, which is characterized in that including following component and its parts by weight: 5-10 parts of rouge
Fat, 20-35 part carbohydrate, 45-55 parts of dietary fibers, 0.005-0.02 parts of liposoluble vitamins, 0.008-0.2 parts it is water-soluble
Property vitamin, 2-6 parts of diet essence, 0.1-8 parts of integration of drinking and medicinal herbs ingredients, the new money of 0.1-2 parts of natural plants compounds and 1-7 parts
Source food;
Wherein, the integration of drinking and medicinal herbs ingredient include cassia seed, endothelium corneum gigeriae galli, dandelion, Poria cocos, semen ziziphi spinosae, radish seed, brush-cherry seed,
At least one of peach kernel, Chinese yam, oyster, black pepper, Radix Glycyrrhizae, the sophora bud, peppermint, lily, dried orange peel, root of Dahurain angelica;
Wherein, the new resource food include first milk basic protein, γ-aminobutyric acid, chitosan oligosaccharide, eucommia Bark male flower, bamboo-leaves flavones,
Casein phosphopeptide, avenabeta glucosan, yeast beta-dextran, newborn mineral salt, pueraria root powder, Rosa roxburghii Tratt, xylo-oligosaccharide, the luxuriant Chinese herbaceous peony of circle
At least one of sub- shell, Noni puree, lactobacillus.
2. constipation tailored version clinical nutrition formula according to claim 1, which is characterized in that the dietary fiber includes chrysanthemum
Powder and galactooligosaccharide.
3. constipation tailored version clinical nutrition formula according to claim 1, which is characterized in that in the liposoluble vitamin
Including 0.005-0.01 parts of vitamin Es.
4. constipation tailored version clinical nutrition formula according to claim 1, which is characterized in that the integration of drinking and medicinal herbs is at subpackage
Include cassia seed, endothelium corneum gigeriae galli, radish seed, dandelion, brush-cherry seed, peach kernel.
5. constipation tailored version clinical nutrition formula according to claim 4, which is characterized in that the integration of drinking and medicinal herbs ingredient is also
Including the sophora bud, peppermint, semen ziziphi spinosae, lily, dried orange peel, the root of Dahurain angelica.
6. constipation tailored version clinical nutrition formula according to claim 4 or 5, which is characterized in that the integration of drinking and medicinal herbs at
The parts by weight of cassia seed, endothelium corneum gigeriae galli, radish seed, dandelion, brush-cherry seed, peach kernel in point are as follows: 0.1-1 parts of cassia seed, endothelium corneum gigeriae galli
0.1-1 parts, 0.1-1 parts of radish seed, 0.1-1 parts of dandelion, 0.1-1 parts of brush-cherry seed, 0.1-1 parts of peach kernel.
7. constipation tailored version clinical nutrition formula according to claim 1, which is characterized in that the lactobacillus includes acidophilus
At least one of lactobacillus, lactobacillus plantarum, Lactobacillus rhamnosus.
8. constipation tailored version clinical nutrition formula according to claim 1, which is characterized in that the new resource food includes
Chitosan oligosaccharide, circle luxuriant isapgol husk, Noni puree, lactobacillus acidophilus, lactobacillus plantarum, Lactobacillus rhamnosus, avenabeta glucosan.
9. constipation tailored version clinical nutrition formula according to claim 8, which is characterized in that shell in the new resource food
Oligosaccharides, circle luxuriant isapgol husk, Noni puree, lactobacillus acidophilus, lactobacillus plantarum, Lactobacillus rhamnosus, avenabeta glucosan
Parts by weight are as follows: chitosan oligosaccharide 0.1-0.5, circle luxuriant 3-5 parts of isapgol husk, 0.1-1 parts of Noni puree, lactobacillus acidophilus 0.01-
0.03 part, 0.01-0.02 parts of lactobacillus plantarum, 0.01-0.02 parts of Lactobacillus rhamnosus, 0.1-1 parts of avenabeta glucosan.
10. the preparation method of constipation tailored version clinical nutrition formula according to claim 1 to 9, feature exist
In including the following steps:
Step 1, fat powder is prepared;
Step 2, integration of drinking and medicinal herbs ingredient and vitamin are prepared into powder particle diameter is 60~80 mesh powders;
Step 3, the carbohydrate of predetermined weight, dietary fiber, diet essence, natural plants compound and new resources are eaten
Product are prepared into the powder that powder particle diameter is 150~250 μm respectively;
Step 4, powder obtained by step 1~3 is sequentially added into mixing machine and is uniformly mixed obtained formula mixture, by sterilization
It is spare after processing;
Step 5, the formula mixture is prepared into nutrient powder, nutrition emulsion, capsule, tablet, pill or oral solution
It is at least one;
Wherein, the sequence of step 1~3 can be replaced mutually.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811237151.3A CN109349618A (en) | 2018-10-23 | 2018-10-23 | Constipation tailored version clinical nutrition formula and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811237151.3A CN109349618A (en) | 2018-10-23 | 2018-10-23 | Constipation tailored version clinical nutrition formula and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109349618A true CN109349618A (en) | 2019-02-19 |
Family
ID=65346310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811237151.3A Pending CN109349618A (en) | 2018-10-23 | 2018-10-23 | Constipation tailored version clinical nutrition formula and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109349618A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110801017A (en) * | 2019-11-06 | 2020-02-18 | 湖北中医药大学 | Chitosan oligosaccharide composition for improving constipation and application thereof |
CN111298021A (en) * | 2020-04-07 | 2020-06-19 | 湖南中医药大学第一附属医院((中医临床研究所)) | Traditional Chinese medicine composition for treating functional constipation |
CN112715669A (en) * | 2020-11-24 | 2021-04-30 | 本溪木兰花乳业有限责任公司 | Milk product for improving constipation and preparation method thereof |
CN113318168A (en) * | 2021-06-08 | 2021-08-31 | 深圳市龙岗区妇幼保健院 | Composition for improving intractable constipation and application thereof |
CN116726054A (en) * | 2022-12-05 | 2023-09-12 | 山东新时代药业有限公司 | Instant probiotic composition and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107440120A (en) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | A kind of children's monophagia and anorexia tailored version clinical nutrition formula particular about food and preparation method thereof |
CN108013452A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | A kind of puerperal abdominal flatulence gas tailored version clinical nutrition formula and preparation method thereof |
CN108013454A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | Gynaecological imflammation tailored version clinical nutrition formula and preparation method thereof |
CN108077911A (en) * | 2017-12-13 | 2018-05-29 | 上海奥医生物医药科技有限公司 | A kind of epileptic's tailored version clinical nutrition formula and preparation method thereof |
CN108618129A (en) * | 2018-05-10 | 2018-10-09 | 上海奥医生物医药科技有限公司 | Sarcopenia tailored version clinical nutrition formula and preparation method thereof |
-
2018
- 2018-10-23 CN CN201811237151.3A patent/CN109349618A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107440120A (en) * | 2017-08-23 | 2017-12-08 | 上海奥医生物医药科技有限公司 | A kind of children's monophagia and anorexia tailored version clinical nutrition formula particular about food and preparation method thereof |
CN108013452A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | A kind of puerperal abdominal flatulence gas tailored version clinical nutrition formula and preparation method thereof |
CN108013454A (en) * | 2017-12-13 | 2018-05-11 | 上海奥医生物医药科技有限公司 | Gynaecological imflammation tailored version clinical nutrition formula and preparation method thereof |
CN108077911A (en) * | 2017-12-13 | 2018-05-29 | 上海奥医生物医药科技有限公司 | A kind of epileptic's tailored version clinical nutrition formula and preparation method thereof |
CN108618129A (en) * | 2018-05-10 | 2018-10-09 | 上海奥医生物医药科技有限公司 | Sarcopenia tailored version clinical nutrition formula and preparation method thereof |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110801017A (en) * | 2019-11-06 | 2020-02-18 | 湖北中医药大学 | Chitosan oligosaccharide composition for improving constipation and application thereof |
CN111298021A (en) * | 2020-04-07 | 2020-06-19 | 湖南中医药大学第一附属医院((中医临床研究所)) | Traditional Chinese medicine composition for treating functional constipation |
CN112715669A (en) * | 2020-11-24 | 2021-04-30 | 本溪木兰花乳业有限责任公司 | Milk product for improving constipation and preparation method thereof |
CN113318168A (en) * | 2021-06-08 | 2021-08-31 | 深圳市龙岗区妇幼保健院 | Composition for improving intractable constipation and application thereof |
CN116726054A (en) * | 2022-12-05 | 2023-09-12 | 山东新时代药业有限公司 | Instant probiotic composition and preparation method and application thereof |
CN116726054B (en) * | 2022-12-05 | 2024-03-26 | 山东新时代药业有限公司 | Instant probiotic composition and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109349618A (en) | Constipation tailored version clinical nutrition formula and preparation method thereof | |
CN107496850B (en) | It is a kind of adjust enteral microecological formulation formula and application | |
CN105249326A (en) | Fermented fruit and vegetable composition containing probiotics and traditional Chinese medicine extract and preparation method of fermented fruit and vegetable composition | |
CN102068707B (en) | Traditional Chinese medicine contrast medium adjuvant used for B ultrasonic and preparation method thereof | |
CN109123643A (en) | A kind of preparation method of cereal generation meal ball | |
CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
CN106722206A (en) | A kind of composition for alleviating alimentary canal malaise symptoms and/or emotional stress and products thereof | |
CN107259571A (en) | One kind is for canteen thing and preparation method thereof | |
CN108013454A (en) | Gynaecological imflammation tailored version clinical nutrition formula and preparation method thereof | |
CN110447902B (en) | Composition with weight-losing effect | |
CN106173733A (en) | A kind of Auricularia health-care beverage and preparation method thereof | |
CN107183705A (en) | A kind of relax bowel improves the functional food of constipation | |
CN111053190A (en) | Light-weight food composition for weight-losing meal replacement and preparation method thereof | |
CN107373672A (en) | A kind of irregular menstruation women tailored version clinical nutrition formula and preparation method thereof | |
CN106418501A (en) | Healthcare food with weight reducing function | |
CN104324189A (en) | Intestine-moistening and bowel-releasing health-caring product | |
Tabrizi et al. | Functional laxative foods: Concepts, trends and health benefits | |
CN105056005B (en) | A kind of integration of drinking and medicinal herbs composition of energy lower blood-fat and reduce weight | |
CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
Sharma et al. | Role of Functional Foods in Human Health and Disease Prevention | |
CN110638038A (en) | Medical formula nutritional meal replacement powder for controlling hyperglycemia and preparation method thereof | |
CN108245531B (en) | Composition for improving gastrointestinal tract function and preventing and treating constipation | |
CN109497563A (en) | Leucoderma tailored version clinical nutrition formula and preparation method thereof | |
CN115399476A (en) | Food composition with auxiliary bowel relaxing function | |
CN114191515A (en) | Oral gel for dispelling dampness, invigorating stomach and improving immunity and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190219 |
|
RJ01 | Rejection of invention patent application after publication |